Free Trial Request
Thursday, November 24, 2016
Wednesday, November 9, 2016
Call For Paper
Bentham Science Publishers would like to invite you to submit your research paper for publishing in the Journal of
Wednesday, November 2, 2016
Highlighted Article: Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid
Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid
Author(s):
Tiziana M.G. Pecora, Teresa Musumeci, Lucrezia Musumeci, Massimo Fresta and Rosario Pignatello Pages 1165 - 1175 ( 11 )
Abstract:
Background: Microencapsulation of natural antioxidants in polymeric systems represents a possible strategy for improving the oral bioavailability of compounds that are otherwise poorly soluble.
Objective: α-lipoic acid (ALA) was microencapsulated with polymethacrylate polymers (blends at various ratios of Eudragit® RS100 and RL100 resins).
Method: Microspheres were produced by solvent displacement of an ethanol cosolution of ALA and polymers; the microsuspensions were then freeze-dried, using trehalose as a cryoprotector. Microspheres were characterized in the solid state for micromeritic properties and drug loading, as well as by infrared spectroscopy, powder X-ray diffractometry and differential scanning calorimetry. The antioxidant activity of free and encapsulated ALA was assessed by the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay.
Results: In vitro release studies, performed in simulated gastric (pH 1.2) and intestinal fluid (pH 6.8), showed that, depending on polymer composition and drug-to-polymer ratio, ALA release can be slowed down, compared to the dissolution pattern of the free drug. Solid-state characterization confirmed the chemical stability of ALA in the microspheres, suggesting that ALA did not develop strong interactions with the polymer and was present in an amorphous or a disordered-crystalline state within the polymer network. As indicated by the DPPH assay, the microencapsulation of ALA in Eudragit® Retard matrices did not alter its antioxidant activity.
Conclusion: ALA was effectively encapsulated in Eudragit® Retard matrices, showing a chemical stability up to 6 months at room conditions and at 40°C. Moreover, since the drug maintained its antioxidant activity in vitro, the potential application of these microparticulate systems for oral administration would deserve further studies.
Keywords:
Antioxidant activity, coevaporates, DPPH assay, Eudragit® Retard, lipoic acid, microencapsulation, polymers.
Affiliation:
Department of Drug Sciences, University of Catania, Viale A. Doria, 6; I-95125 Catania, Italy.
Graphical Abstract:
For More Information Please Visit Our Website Current Drug Delivery
